FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously undergone preclinical and clinical development for oncology indications and has completed a Phase 1a clinical trial in ovarian cancer patients and other advanced solid tumours. METHODS: In vitro, cancer stem cell (CSC...

Full description

Saved in:
Bibliographic Details
Published in:Br J Cancer
Main Authors: Annett, Stephanie, Moore, Gillian, Short, Amy, Marshall, Andrea, McCrudden, Cian, Yakkundi, Anita, Das, Sudipto, McCluggage, W. Glenn, Nelson, Laura, Harley, Ian, Moustafa, Nermeen, Kennedy, Catherine J., deFazio, Anna, Brand, Alison, Sharma, Raghwa, Brennan, Donal, O’Toole, Sharon, O’Leary, John, Bates, Mark, O’Riain, Ciarán, O’Connor, Darran, Furlong, Fiona, McCarthy, Helen, Kissenpfennig, Adrien, McClements, Lana, Robson, Tracy
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7000737/
https://ncbi.nlm.nih.gov/pubmed/31772325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0649-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items